Nell Greenfieldboyce

Nell Greenfieldboyce is a NPR science correspondent.

With reporting focused on general science, NASA, and the intersection between technology and society, Greenfieldboyce has been on the science desk's technology beat since she joined NPR in 2005.

In that time Greenfieldboyce has reported on topics including the narwhals in Greenland, the ending of the space shuttle program, and the reasons why independent truckers don't want electronic tracking in their cabs.

Much of Greenfieldboyce's reporting reflects an interest in discovering how applied science and technology connects with people and culture. She has worked on stories spanning issues such as pet cloning, gene therapy, ballistics, and federal regulation of new technology.

Prior to NPR, Greenfieldboyce spent a decade working in print, mostly magazines including U.S. News & World Report and New Scientist.

A graduate of Johns Hopkins, earning her Bachelor's of Arts degree in social sciences and a Master's of Arts degree in science writing, Greenfieldboyce taught science writing for four years at the university. She was honored for her talents with the Evert Clark/Seth Payne Award for Young Science Journalists.

One of the reasons Ebola is so terrifying is that there's no vaccine and no cure. But the World Health Organization hopes to change that, with plans to quickly test experimental products during this outbreak.

By November, two promising vaccines will have been tested on people to see if they're safe, says Marie-Paule Kieny, assistant director-general at WHO.

The latest numbers on the Ebola outbreak are grim: 2,473 people infected and 1,350 deaths.

That's the World Health Organization's official tally of confirmed, probable and suspect cases across Guinea, Liberia, Sierra Leone and Nigeria. But the WHO has previously warned that its official figures may "vastly underestimate the magnitude of the outbreak."

So how bad is it really?

While the Ebola outbreak continues to rage in West Africa, it is also unfolding — in a virtual sense — inside the computers of researchers who study the dynamics of epidemics.

Policymakers look to these simulations to get a sense of how the outbreak might spread. They also can use them to run experiments to see which public health measures should take priority.

A smoldering debate about whether researchers should ever deliberately create superflu strains and other risky germs in the interest of science has flared once again.

ROBERT SIEGEL, HOST:

From NPR News, this is ALL THINGS CONSIDERED. I'm Robert Siegel.

MELISSA BLOCK, HOST:

And I'm Melissa Block. The Ebola outbreak in West Africa continues to grow. The World Health Organization says nearly 2,000 people are known to have the virus, and of those, over 1,000 have died. Now an ethics panel convened by the WHO is looking into the use of experimental vaccines and drugs, and it has endorsed using them if certain conditions are met. NPR's Nell Greenfieldboyce reports.

A panel of experts convened by the World Health Organization has unanimously endorsed the idea of offering unproven vaccines or treatments to help combat the unprecedented Ebola outbreak in West Africa.

This outbreak is unusual not just because it has spread to four countries and involves so many people, says Dr. Marie-Paule Kieny, Assistant Director-General at the World Health Organization. It is also the first Ebola outbreak that could possibly benefit from a range of potential experimental treatments and vaccines.

Pages